Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05610319 · ClinicalTrials.gov registry record · Phase 4
Treat & Extend Versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: a Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial
A Phase 4 study of Diabetic Macular Edema, sponsored by McMaster University.
- Active
- Registry status
- Phase 4
- Development phase
- 446
- Enrollment target
- 20
- Study locations
NCT05610319 is a Phase 4 study of Diabetic Macular Edema that is active but no longer recruiting, run by McMaster University. The registered enrollment target is 446 participants, below the 3,787-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT05610319, a Phase 4 study of Diabetic Macular Edema, is active but no longer recruiting, sponsored by McMaster University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 446 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess a pragmatic, treat and extend regimen of faricimab against the standard of a fixed dosing regimen.
Conditions Studied
Interventions
- DRUG Faricimab
Study Locations (20)
New South Wales
- Eye Clinic Albury Wodonga - Albury
- Nexus Eyecare Blacktown - Blacktown
- Eastern Suburbs Eye Specialists - Bondi Junction
- Retina and Eye Consultants - Hurstville
- Lane Cove Eye - Lane Cove
- South West Retina - Liverpool
- Marsden Eye Specialists - Parramatta
- Strathfield Retina Clinic - Strathfield
- South Eastern Sydney Health - Sydney
Texas
- Austin Retina Associates - Austin
- Retina Consultants of Texas - Beaumont
- Retina & Vitreous of Texas - Bellaire
- Retina Consultants of Houston, dba Retina Consultants of Texas - Bellaire
- Valley Retina Institute - McAllen
- Retina Consultants of Houston, dba Retina Consultants of Texas - San Antonio
California
- Retinal Consultants Medical Group Inc. - Modesto
- Vitreo-Retina Medical Group - Sacramento
Illinois
- University Retina and Macula Associates - Oak Forest
Louisiana
- Eye Associates of Northeast Louisiana Dba Haik Humble Eye Center - West Monroe
Mississippi
- Mississippi Retina Associates - Jackson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 446 participants |
| Start Date | 2023-05-01 |
| Est. Completion | 2026-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05610319
The ClinicalTrials.gov registry entry for NCT05610319 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 446 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,787-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (88% lower). The listed sponsor is McMaster University, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetic Macular Edema appearing as the primary indexed condition, and to 1 intervention - of which Faricimab is the first listed.
NCT05610319 reports 20 study locations spanning 6 distinct geographic areas - top geographies include New South Wales, Texas, California.
Frequently Asked Questions
What is clinical trial NCT05610319 about?
NCT05610319 is a clinical study titled "Treat & Extend Versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: a Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial". This study will assess a pragmatic, treat and extend regimen of faricimab against the standard of a fixed dosing regimen.
What is the current status of trial NCT05610319?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 446 participants. The study started on 2023-05-01. Estimated completion is 2026-12.
What conditions does trial NCT05610319 study?
This clinical trial studies the following conditions: Diabetic Macular Edema.
What interventions are being tested in trial NCT05610319?
The interventions under investigation include: Faricimab (DRUG).
Who is sponsoring clinical trial NCT05610319?
This trial is sponsored by McMaster University, which has 31 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05610319 being conducted?
This trial has 20 study locations across California, Illinois, Louisiana, Mississippi, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
ACTIVE NOT RECRUITING · Phase 4
-
A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)
ACTIVE NOT RECRUITING · Phase 4
-
Ocular Safety and Usability Study for FYB203 PFS
COMPLETED · Phase 4
-
Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis
COMPLETED · Phase 4
-
IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab
COMPLETED · Phase 4
-
Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.